Purpose: The aim of this study was to evaluate the relationship between the intravitreal vascular endothelial growth factor (VEGF) level and prognosis of proliferative diabetic retinopathy (PDR). Methods: The study involved 136 eyes of 114 PDR patients who underwent an initial vitrectomy between 2006 and 2008. Intravitreal VEGF levels were determined using Bio-Plex® (Bio-Rad), with levels of 5,000 pg/mL or more classified as high-VEGF (45 eyes) and levels lower than 5,000 pg/mL as low-VEGF (91 eyes). Diabetic control, PDR severity, and frequency of postoperative complications were compared between the groups. Results: There was no significant difference in preoperative status between the groups. In the low-VEGF group, a reoperation was required due to postoperative complications in 2 eyes (2.2%); 1 with vitreous hemorrhage (VH) and 1 with retinal detachment (RD). In contrast, a reoperation was required in 8 eyes (17.8%) in the high-VEGF group; 3 with VH, 2 with RD, and 3 with neovascular glaucoma. The difference between the groups was significant. There was a statistically lower postoperative corrected visual acuity logMAR (6 months after surgery) in the high-VEGF than in the low-VEGF group (p = 0.02, unpaired t test). Conclusion: Current findings indicate that careful observation is needed in patients with elevated VEGF levels.

Keywords:
Diabetic retinopathy, Vitrectomy, Vascular endothelial growth factor
1.
Aiello LP, Avery RL, Arrigg PG, et al: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-1487.
2.
Ogata N, Nishikawa M, Nishimura T, et al: Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol 2002;134:348-353.
3.
Yoshimura T, Sonoda K, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, Ueno A, Hata Y, Yoshida H, Ishibashi T: Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158.
4.
Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y: Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol 2011;55:256-263.
5.
Loukovaara S, Robciuc A, Holopainen JM, Lehti K, Pessi T, Liinamaa J, Kukkonen K, Jauhiainen M, Koli K, Keski-Oja J, Immonen I: Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol 2013;91:531-539.
6.
Maier R, Weger M, Haller-Schober E, El-Shabrawi Y, Theisl A, Barth A, Aigner R, Haas A: Application of multiplex cytometric bead array technology for the measurement of angiogenic factors in the vitreous. Mol Vis 2006;12:1143-1147.
7.
Adamiec-Mroczek J, Oficjalska-Mlyńczak J, Misiuk-Hojło M: Roles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: analysis of vitreous samples. Cytokine 2010;49:269-274.
8.
Hernández C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simó R: Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med 2005;22:719-722.
9.
Katsura Y, Okano T, Matsuno K, et al: Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care 2005;28:2252-2254.
10.
Watanabe D, Suzuma K, Matsui S, et al: Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-792.
11.
Takagi H, Watanabe D, Suzuma K, et al: Novel role of erythropoietin in proliferative diabetic retinopathy. Diabetes Res Clin Pract 2007;77(suppl 1):S62-S64.
12.
Praidou A, Klangas I, Papakonstantinou E, Androudi S, Georgiadis N, Karakiulakis G, Dimitrakos S: Vitreous and serum levels of platelet-derived growth factor and their correlation in patients with proliferative diabetic retinopathy. Curr Eye Res 2009;34:152-161.
13.
Roldán-Pallarés M, Rollín R, Martínez-Montero JC, Fernández-Cruz A, Bravo-Llata C, Fernández-Duango R: Immunoreactive endothelin-1 in the vitreous humor and epiretinal membranes of patients with proliferative diabetic retinopathy. Retina 2007;27:222-235.
14.
Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J: Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica 2001;215:415-418.
15.
Yoshida S, Ishikawa K, Matsumoto T, Yoshida A, Ishibashi T, Kono T: Reduced concentrations of angiogenesis-related factors in vitreous with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2010;248:799-804.
16.
Yokoi M, Yamagishi S, Saito A, Yoshida Y, Maysui T, Saito W, Hirose S, Ohgami K, Kase M, Ohno S: Positive association of pigment actor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2007;91:885-887.
17.
Wakabayashi Y, Usui Y, Okunuki Y, Ueda S, Kimura K, Muramatsu D, Kezuka T, Goto H: Intraocular VEGF level as a risk factor for postoperative complications after vitrectomy for proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 2012;53:6403-6410.
18.
Funatsu H, Yamashita H, Noma H, Mochizuki H, Mimura T, Ikeda T, Hori S: Outcome of vitreous surgery and the balance between vascular endothelial growth factor and endostatin. Invest Ophthalmol Vis Sci 2003;44:1042-1047.
19.
Wang J, Chen S, Jiang F, You C, Mao C, Yu J, Han J, Zhang Z, Yan H: Vitreous and plasma VEGF levels as predictive factors in the progression of proliferative diabetic retinopathy after vitrectomy. PLoS One 2014;9:e110531.
20.
Suzuki Y, Suzuki K, Yokoi Y, Miyagawa Y, Metoki T, Nakazawa M: Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy. Retina 2014;34:165-171.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.